PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor
Background: Gliomas are aggressive tumors with various molecular and clinical characteristics and exhibit strongly resistance to radio-chemotherapy. Programmed cell death 1 ligand 2 (PD-L2) is a cell surface protein, which was reported in many cancers, modulating cancer-associated immune responses,...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-02-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/2162402X.2018.1541535 |
| _version_ | 1828170464209403904 |
|---|---|
| author | Zhi-liang Wang Guan-zhang Li Qiang-wei Wang Zhao-shi Bao Zheng Wang Chuan-bao Zhang Tao Jiang |
| author_facet | Zhi-liang Wang Guan-zhang Li Qiang-wei Wang Zhao-shi Bao Zheng Wang Chuan-bao Zhang Tao Jiang |
| author_sort | Zhi-liang Wang |
| collection | DOAJ |
| description | Background: Gliomas are aggressive tumors with various molecular and clinical characteristics and exhibit strongly resistance to radio-chemotherapy. Programmed cell death 1 ligand 2 (PD-L2) is a cell surface protein, which was reported in many cancers, modulating cancer-associated immune responses, while the role of PD-L2 in gliomas remained unclear. Herein, we aimed to investigate the biological behaviors and clinical prognostic values of PD-L2 in gliomas. Methods: Totally, we enrolled RNA sequencing data of 325 glioma samples from Chinese Glioma Genome Atlas (CGGA) as training cohort and RNA expression data of 1032 samples from The Cancer Genome Atlas (TCGA) dataset as validation cohort in this research. Then, the clinical and molecular characteristics, and the prognostic value of PD-L2 were analyzed. Results: We found that PD-L2 expression level was significantly upregulated in higher grade glioma and IDH wild-type glioma. Receiver Operating Characteristic (ROC) analysis revealed that PD-L2 was a potential indicator of mesenchymal subtype. PD-L2 exhibited tight relationship with immune response and immune-modulating process in glioma. Moreover, PD-L2 expression level could predict unfavorable prognoses of patients independent of age, grade, IDH status and 1p/19q status. Conclusions: Our study revealed that PD-L2 was closely related with inflammation and immune response. Patients with lower PD-L2 expression level tended to experience improved survival. Targeting PD-L2 may become a valuable approach for the treatment of gliomas in clinical practice. |
| first_indexed | 2024-04-12T03:10:39Z |
| format | Article |
| id | doaj.art-4223db8318bb47e281c84cc83b64d85b |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-04-12T03:10:39Z |
| publishDate | 2019-02-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-4223db8318bb47e281c84cc83b64d85b2022-12-22T03:50:21ZengTaylor & Francis GroupOncoImmunology2162-402X2019-02-018210.1080/2162402X.2018.15415351541535PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factorZhi-liang Wang0Guan-zhang Li1Qiang-wei Wang2Zhao-shi Bao3Zheng Wang4Chuan-bao Zhang5Tao Jiang6Capital Medical UniversityCapital Medical UniversityCapital Medical UniversityCapital Medical UniversityCapital Medical UniversityCapital Medical UniversityCapital Medical UniversityBackground: Gliomas are aggressive tumors with various molecular and clinical characteristics and exhibit strongly resistance to radio-chemotherapy. Programmed cell death 1 ligand 2 (PD-L2) is a cell surface protein, which was reported in many cancers, modulating cancer-associated immune responses, while the role of PD-L2 in gliomas remained unclear. Herein, we aimed to investigate the biological behaviors and clinical prognostic values of PD-L2 in gliomas. Methods: Totally, we enrolled RNA sequencing data of 325 glioma samples from Chinese Glioma Genome Atlas (CGGA) as training cohort and RNA expression data of 1032 samples from The Cancer Genome Atlas (TCGA) dataset as validation cohort in this research. Then, the clinical and molecular characteristics, and the prognostic value of PD-L2 were analyzed. Results: We found that PD-L2 expression level was significantly upregulated in higher grade glioma and IDH wild-type glioma. Receiver Operating Characteristic (ROC) analysis revealed that PD-L2 was a potential indicator of mesenchymal subtype. PD-L2 exhibited tight relationship with immune response and immune-modulating process in glioma. Moreover, PD-L2 expression level could predict unfavorable prognoses of patients independent of age, grade, IDH status and 1p/19q status. Conclusions: Our study revealed that PD-L2 was closely related with inflammation and immune response. Patients with lower PD-L2 expression level tended to experience improved survival. Targeting PD-L2 may become a valuable approach for the treatment of gliomas in clinical practice.http://dx.doi.org/10.1080/2162402X.2018.1541535gliomaimmune responsepd-l2checkpoint inhibitor |
| spellingShingle | Zhi-liang Wang Guan-zhang Li Qiang-wei Wang Zhao-shi Bao Zheng Wang Chuan-bao Zhang Tao Jiang PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor OncoImmunology glioma immune response pd-l2 checkpoint inhibitor |
| title | PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor |
| title_full | PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor |
| title_fullStr | PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor |
| title_full_unstemmed | PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor |
| title_short | PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor |
| title_sort | pd l2 expression is correlated with the molecular and clinical features of glioma and acts as an unfavorable prognostic factor |
| topic | glioma immune response pd-l2 checkpoint inhibitor |
| url | http://dx.doi.org/10.1080/2162402X.2018.1541535 |
| work_keys_str_mv | AT zhiliangwang pdl2expressioniscorrelatedwiththemolecularandclinicalfeaturesofgliomaandactsasanunfavorableprognosticfactor AT guanzhangli pdl2expressioniscorrelatedwiththemolecularandclinicalfeaturesofgliomaandactsasanunfavorableprognosticfactor AT qiangweiwang pdl2expressioniscorrelatedwiththemolecularandclinicalfeaturesofgliomaandactsasanunfavorableprognosticfactor AT zhaoshibao pdl2expressioniscorrelatedwiththemolecularandclinicalfeaturesofgliomaandactsasanunfavorableprognosticfactor AT zhengwang pdl2expressioniscorrelatedwiththemolecularandclinicalfeaturesofgliomaandactsasanunfavorableprognosticfactor AT chuanbaozhang pdl2expressioniscorrelatedwiththemolecularandclinicalfeaturesofgliomaandactsasanunfavorableprognosticfactor AT taojiang pdl2expressioniscorrelatedwiththemolecularandclinicalfeaturesofgliomaandactsasanunfavorableprognosticfactor |